Skip to main content

Visceral Leishmaniasis

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Aurobindo Pharma
Aurobindo PharmaIndia - Hyderabad
1 program
1
Amphotericin B LiposomePhase 11 trial
Active Trials
NCT03636659Completed140Est. Apr 2019
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Immunogenetics of Visceral LeishmaniasisN/A1 trial
Active Trials
NCT00342823Completed7,000Est. Jun 2010
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Immunogenetics of Visceral LeishmaniasisN/A
Hope Medicine
Hope MedicineChina - Pudong
1 program
rk28 ICTN/A1 trial
Active Trials
NCT01766830Completed1,927Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Aurobindo PharmaAmphotericin B Liposome
Hope Medicinerk28 ICT
Human BioSciencesImmunogenetics of Visceral Leishmaniasis

Clinical Trials (3)

Total enrollment: 9,067 patients across 3 trials

NCT03636659Aurobindo PharmaAmphotericin B Liposome

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

Start: May 2018Est. completion: Apr 2019140 patients
Phase 1Completed
NCT01766830Hope Medicinerk28 ICT

Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)

Start: Jan 2013Est. completion: Jul 20161,927 patients
N/ACompleted
NCT00342823Human BioSciencesImmunogenetics of Visceral Leishmaniasis

Immunogenetics of Visceral Leishmaniasis

Start: Oct 2003Est. completion: Jun 20107,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.